Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
Gross Margin: Approximately 93% for the third quarter. Gross to Net Discount: Approximately 40%, with an adjustment leading to a reduction of about 3% or $2 million. Operating Expenses: Approximately $73.3 million for the third quarter. Cash and Marketable Securities: $317 million at the end of the third quarter. Sales Force Expansion: Increased from approximately 100 to 150 by the end of the third quarter. Coverage: Secured additional commercial and two large Medicare contracts, covering more than 80% of patient lives. Fourth Quarter Guidance: Expected 50,000 to 55,000 bottles to be delivered to patients. Expected Gross to Net Discount: Range of approximately 42% to 46% for the fourth quarter. Warning! GuruFocus has detected 5 Warning Signs with TARS. Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Tarsus Pharmaceuticals Inc ( NASDAQ:TARS ) reported its most successful quarter t
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Breakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) [Yahoo! Finance]Yahoo! Finance
- Tarsus to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Tarsus to Participate in Upcoming Investor ConferencesGlobeNewswire
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Barclays PLC from $60.00 to $62.00. They now have an "overweight" rating on the stock.MarketBeat
TARS
Earnings
- 11/13/24 - Beat
TARS
Sec Filings
- 2/13/25 - Form SCHEDULE
- 1/17/25 - Form 8-K
- 1/13/25 - Form 8-K
- TARS's page on the SEC website